FDA Approves Nexplanon for Five Years of Contraception, Up From Three

The U.S. Food and Drug Administration has officially extended the approved duration of use for Nexplanon, the widely used birth control implant, from three years to up to five years. The regulatory update, announced by manufacturer Organon, aligns the device’s official prescribing label with years of accumulated clinical evidence. For millions of women relying on the single-rod subdermal contraceptive, the approval means fewer replacement procedures, lower long-term healthcare costs, and uninterrupted pregnancy prevention. The decision marks a significant milestone in reproductive health, ensuring that one of the most effective forms of birth control is now officially recognized for its true longevity.[1][2][3]

The decision bridges a longstanding gap between clinical practice and regulatory guidelines. For years, many reproductive health providers have counseled patients that the implant remains highly effective well beyond its original three-year indication, relying on independent studies and off-label use to guide their recommendations. By officially updating the label, the FDA has formalized this extended timeline, a move that carries significant implications for the healthcare system. It standardizes clinical protocols across different practices, ensures that insurance companies will reliably cover the device for its full lifespan, and provides patients with the regulatory reassurance that their contraceptive method is backed by the highest level of federal scrutiny.[4]

Nexplanon is a long-acting reversible contraceptive (LARC) that takes the form of a small, flexible, radiopaque rod, roughly the size of a matchstick. It is inserted just under the skin of the inner, non-dominant upper arm during a brief, minimally invasive in-office procedure. Once in place, the implant provides continuous, low-maintenance birth control without requiring daily adherence, making it one of the most effective contraceptive methods available. Because it is radiopaque, clinicians can easily verify its presence using a standard two-dimensional X-ray, ultrasound, or MRI if it cannot be felt beneath the skin.[1]

The implant works by slowly releasing a steady, continuous dose of etonogestrel, a synthetic progestin hormone, directly into the bloodstream. This hormone prevents pregnancy through a highly effective dual mechanism. Primarily, it suppresses the release of luteinizing hormone from the pituitary gland, thereby stopping ovulation so that the ovaries do not release an egg. Secondarily, the progestin significantly thickens the cervical mucus, creating a dense physical barrier that makes it exceptionally difficult for sperm to swim into the uterus and reach any potentially released egg.[4]

The FDA’s decision to extend the approval was anchored by a pivotal multicenter, single-arm, open-label clinical trial conducted across the United States. The study specifically enrolled 399 women, with a mean age of 27, who had already been using the Nexplanon implant for a full 36 months—the maximum duration allowed under the previous label. Researchers then monitored these participants closely through their fourth and fifth years of continuous use to rigorously evaluate both the ongoing contraceptive efficacy and the long-term safety profile of the aging implants.

The efficacy results from the extended observation period were definitive. During the fourth and fifth years of continuous use, zero pregnancies were reported among the trial participants. This flawless prevention record yielded a Pearl Index—the standard statistical measure of contraceptive failure rates—of exactly 0.0 pregnancies per 100 women-years of use. The data conclusively confirmed that the implant’s steady hormone release remains more than sufficient to reliably suppress ovulation and prevent pregnancy well past the 36-month mark, validating the off-label advice many clinicians had been providing.[1]

Crucially, the clinical trial addressed historical uncertainties regarding the implant’s effectiveness in patients with higher body weights. Previous contraceptive studies have sometimes struggled to definitively prove efficacy across all weight classes, as hormonal distribution and metabolism can vary significantly depending on a patient's body mass. To resolve this, the Organon trial specifically enrolled women with a remarkably broad range of body mass index (BMI) values, spanning from 17.2 on the lower end up to 64.3 on the higher end.[1][2]

More than 38 percent of the study’s participants had a BMI of 30 or higher, classifying them as obese under standard medical guidelines. The fact that zero pregnancies occurred across this highly diverse cohort provides robust, undeniable evidence that the extended five-year duration is highly effective regardless of a patient’s body weight. This finding is particularly important for health equity, reinforcing the etonogestrel implant as an inclusive, reliable option for comprehensive women’s healthcare across all body types, without requiring weight-based dosage adjustments or earlier replacement schedules.[1]

On the safety front, the clinical trial revealed no new adverse events or unexpected health risks during the fourth and fifth years of use. The side effect profile remained entirely consistent with what patients typically experience during the first three years of having the implant. The most common adverse reaction, and the leading cause for patients choosing to have the device removed early, remains unpredictable changes in menstrual bleeding patterns, which affected a small but notable percentage of the trial cohort.

Beyond bleeding changes, other frequently reported side effects include headaches, vaginitis, weight increase, acne, and breast pain. During the extended use period specifically, intermenstrual bleeding—often referred to as spotting—was the most common specific adverse event, affecting roughly 5.4 percent of users. Despite these known side effects, the overall safety profile was deemed highly favorable for long-term use, with the vast majority of participants tolerating the extended hormonal exposure without requiring medical intervention or early removal. The FDA concluded that the benefits of highly effective, long-term pregnancy prevention far outweighed the manageable side effect profile.[1]

Alongside the extended duration approval, the FDA introduced a significant new regulatory requirement: a mandatory Risk Evaluation and Mitigation Strategy (REMS) program. While the hormonal implant itself is proven safe, the REMS program is specifically designed to mitigate the rare but serious physical complications that can arise from the improper insertion or removal of the device by untrained medical personnel. The FDA utilizes REMS programs to ensure that the benefits of a drug or device continue to outweigh its specific delivery risks.[2][5]

If an implant is inserted too deeply into the arm, it can migrate into the vasculature, potentially reaching the pulmonary artery, or cause localized nerve damage. To prevent these severe outcomes, the FDA now mandates that all healthcare providers who perform Nexplanon insertions or removals must complete a specific certification and clinical training program. Although the device is radiopaque and can be located via imaging if it cannot be felt under the skin, proper initial subdermal placement is critical to avoiding surgical complications.[1][5]

The REMS enrollment period officially opened in late February 2026 and runs through August 23, 2026. Providers have a strict six-month window to complete the required training; those who fail to certify by the deadline will lose the ability to purchase and prescribe the implant entirely. To enforce this, wholesalers and medical distributors are now legally restricted to supplying the device only to certified pharmacies and healthcare providers who have successfully registered with the national REMS database. This closed-loop distribution system guarantees that every patient receiving the implant is treated by a clinician fully vetted in the latest insertion techniques.[5]

For patients currently using Nexplanon, the regulatory update is entirely seamless. The physical implant manufactured by Organon has not changed in its design or hormonal payload, meaning those who already have the device in their arm are automatically cleared to rely on it for five years from their original insertion date. There is no medical need to have the current implant removed and replaced with a 'new' five-year version, sparing millions of women an unnecessary surgical appointment. Clinicians are actively advising patients to simply update their personal health calendars and cancel any premature removal procedures they may have scheduled under the old three-year guidance.[4]

The broader impact of this approval extends deeply into healthcare economics and contraceptive access. By reducing the frequency of replacement procedures from every three years to every five, the update significantly lowers cumulative out-of-pocket costs for patients and reduces the administrative burden on busy clinical schedules. Furthermore, it ensures that insurance companies, which strictly base their coverage policies on FDA-approved labels, will reliably cover the device for its full five-year lifespan without requiring clinicians to fight through prior authorizations to justify off-label use.[4]